The invention relates to a vaccine composition containing: (a) inactivated whole virus; and (b) a stabilising excipient comprising (i) a buffer solution, (ii) a mixture of essential and non-essential amino acids, (iii) a disaccharide, (iv) a polyol, (v) a chelating agent, (vi) urea or a urea derivative, and (vii) a ...

ABSTRACT A lyophilization medium for a microorganism is provided wherein the medium is substantially free of animal-derived products and comprises yeast extract and monosodium glutamate. The lyophilisation medium can be used for cryoprotection of strains of bacteria such as Corynebacterium diphtheriae. Method for p...

A vaccine composition comprising at least one antigen and one adjuvant characterized in that the adjuvant comprises sterile filterable nanoparticles comprising pseudo boehmite and polyacrylate.

The present invention relates to a stabilizer for vaccine compositions comprising one or more live attenuated flaviviruses, to a bulk vaccine composition stabilized with this stabilizer, particularly a dry vaccine composition prepared from this bulk vaccine composition, and to a method for stabilizing one or more li...

Provided herein are compositions and methods for eliciting an immune response against Streptococcus pneumoniac. More particularly, the compositions and methods relate to immunogenic polypeptides, including fragments of PhtD and variants thereof, and nucleic acids, vectors and transfected cells that encode or express...

The invention relates to a method for producing the flu virus, that comprises: a) administering a flu vaccine to hens; b) collecting the eggs of the vaccinated hens; c) triggering the embryogensis process; d) infecting the embryonated eggs by inoculating a flu virus in the allantoic cavity; e) incubating the infecte...

TMThe invention relates to a method for loading and storing a vaccine composition containing the antigen adsorbed on the aluminum adjuvant which (a) comprises (i) loading the composition into a container; and (ii) closing the container with a device in particular acting as a stopper the surface of the device getting...

The present invention relates to polymerized recombinant proteins to recombinant nucleic acids coding for the polymerized recombinant proteins to expression cassettes comprising the recombinant nucleic acids to host cells transformed by the expression cassettes and to a method for multimerizing a recombinant protein...

This disclosure relates to immunogenic composition comprising an isolated immunogenic S pneumoniae PcpA polypeptide and at least one additional antigen (such as for example, an isolated immunogenic S pneumoniae polypeptide selected from the group consisting of the polyhistidine triad family of proteins (eg. PhtD) an...

This disclosure relates to adjuvants for use in immunogenic composition comprising at least one antigen and an aluminum compound comprising hydroxyl groups that has been treated with phosphate, carboxylate, carbonate, sulfate diphosphonate or a mixture of two or more of these compounds and methods of using these com...

The present invention concerns: a) an isolated peptide comprising an amino acid sequence which is at least 90% identical to the VP4 amino acid sequence of a rhinovirus or an isolated polynucleotide comprising a nucleic acid sequence encoding said peptide placed under the control of the elements necessary for its exp...

The present invention relates to a method for producing adherent cells according to which: a. adherent cells are injected into a culture container which contains microcarriers in a culture medium; b. the cells are amplified by performing a plurality of consecutive cell migrations in said same culture container where...

Provided herein are methods for purifying poxviruses using one or more chromatographic steps including, but not limited to, gel filtration and/or ion exchange chromatography.

The present invention relates to an isolated nucleic acid which comprises the DNA sequence SEQ ID No. 1 or its equivalent RNA sequence.

The present invention relates to a process for stabilizing an adjuvant containing vaccine composition, an adjuvanted vaccine composition in dry form and in particular a process for stabilizing an influenza vaccine composition, particularly an adjuvanted influenza vaccine composition in dry form. ...

The present invention relates to an isolated nucleic acid which comprises the DNA sequence SEQ ID NO. 1 or its equivalent RNA sequence.

The subject matter of the invention is a method for purifying the rabies virus, comprising a single step of ion exchange chromatography, said step being a cation exchange chromatography according to which: a) the supernatant of a culture of cells infected with this virus is brought into contact with a cation exchang...

The present invention provides inter alia for a liquid feeding device for the generation of droplets in particular for the use in a process line for the production of freeze dried particles with a droplet ejection section for ejecting liquid droplets in an ejection direction the droplet ejection section comprising a...

The invention relates to a vaccine against N. meningitidis infections, comprising (i) an N. meningitidis LOS especially consisting of a lipid A, an inner core, and an L8-type a chain in which the heptose II residue of the inner core (a) carries a phosphoethanolamine (PEA) substituent in position 0-3, and does not ca...

The subject matter of the invention is a method for detoxification of lipopolysaccharide (LPS) or of lipid A of a gram-negative bacterium, in which the LPS or the lipid A is mixed with a cationic lipid and, optionally, a co-lipid, so as to form a complex in which the LPS or the lipid A is associated with the catio...

The invention relates to a method for admixing the LPS of a gram-negative bacteria, according to which: (i) LPS or LPS liposomes (LPS formulated in liposomes) is/are mixed with the lipidated sub-unit B of the receptor of human transferrine (lipidated TbpB) of Neisseria meningitidis or a lipid fragment thereof; or (i...

NOT SCANNED

Abstract IMMUNIZATION PROTOCOL AGAINST THE 4 DENGUE SEROTYPES The invention relates to a method to induce a protection against the 4 denge serotypes in a patient, comprising; (a) the administration of a monovalent vaccine comprising a vaccine virus of a first dengue serotype, and (b) the administration of a tetrava...

STABILIZING FORMULATIONS FOR RECOMBINANT VIRUSES This invention relates to preparations of viruses, e.g. for vaccine or other pharmaceutical or research use, to their stabilization, and to processes of producing such preparations, as well as to their use, e.g. as vaccines or as virus vectors. The formulations compr...

The invention relates to a pharmaceutical composition comprising at least one vaccine antigen. The inventive composition is characterised in that it also comprises at least one phosphoric ester derivative of phosphatidylcholine with a structure having formula I, wherein: R1 is a lower alkyl; and R2 and R3 are identi...

The present invention provides nucleic acids, proteins and vectors for a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. trachomatis. The method employs a vector containing a nucleotide sequence encoding a ...

A Corynebacterium diphtheriae culture medium for the production of diphtheria toxin and methods for producing the toxin are provided. The medium is substantiality free of animal-derived products and comprises water, a carbohydrate source, a nitrogen source and a number of free amino acids in an initial concentrati...

Abstract METHOD OF IMMUNIZATION AGAINST THE FOUR SEROTYPES OF DENGUE The invention relates to a method of inducing homologous protection against the four serotypes of dengue in a patient, comprising the sequential administration in said patient (i) of a dose of a vaccinal virus of the dengue of a first serotype a...

The invention relates to a culture medium for Haemophilus influenzae type B, characterized in that the source of protein nitrogen is of nonanimal origin and comprises at least one plant peptone, and in that the source of heme comprises protoporphyrin IX. This medium is used in particular for the production of polyri...

The present invention relates to a process for stabilizing an adjuvant containing vaccine composition, an adjuvanted vaccine composition in dry form and in particular a process for stabilizing an influenza vaccine composition, particularly an adjuvanted influenza vaccine composition in dry form. ...

The invention relates to a thermoreversible oil-in-water emulsion which comprises: a TLR4 agonist whose chemical structure does not include a sugar ring, squalene, a nonionic surfactant belonging to the polyoxyethylene alkyl ether chemical group, a hydrophilic surfactant and an aqueous solvent, and which exhibits im...

The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells. The invention further relates to a vaccine composition which comprises a VDV2 strain.

The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 viruse) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells. The invention further relates to a vaccine composition which comprises a VDV1 strain. Figure: none ...

Vitreous compositions of an antigen and adjuvant, and methods for making the compositions are disclosed. Also disclosed are pharmaceutically acceptable formulations of the vitreous compositions, reconstituted liquid formulations of the vitreous compositions, vaccine compositions, and kits containing the vitreous com...

The invention relates to an immunostimulant composition comprising at least one Toll-Like receptor 7 or Toll-Like receptor 8 agonist and a Toll-Like receptor 4 agonist. The inventive composition can also comprise a vaccine antigen.

Abstract Provided herein are compositions and methods for eliciting an immune response against Porphyromonas gingivalis. The compositions and methods relate to P. gingivalis polypeptides and fragments and variants thereof and the corresponding polynucleotides which are useful in the diagnosis  prevention and therap...

The packaging unit includes an inner enclosure (11) within which is contained each said pharmaceutical product (12), a patient or health care professional information leaflet (13) and outer enclosure (14) including: - a first outer enclosure (15) within which is contained said inner enclosure (11); and - a second ou...

The present invention relates to a process for preparing a porphyrin of formula (I), optionally in the form of a salt with an alkali metal and/or in the form of a metal complex, in which: R and R" are as defined in claim 1, comprising: a condensation step, in an acidic medium, between a dipyrromethane of for...

The disclosure relates to novel lipidic compounds, lipid nanoparticles (LNPs) containing thereof, and the use of the lipidic compounds or the LNPs for the delivery of nucleic acid. The lipidic compounds as disclosed herein comprise at least one terminal radical of formula (I): *-NH-CX-(NH)n-A (I) wherein: - *- repre...

The invention particularly relates to multivalent vaccine compositions capable of treating or preventing at least 60% and preferably 75% of the infections caused by Neisseria meningitidis, in particular those of serogroup B. To this end, the invention substantially relates to lipooligosaccharide (LOS) of N. meningit...

The invention relates to an immunogenic composition comprising an HCMV gB antigen, an HCMV gH/gL/UL128/UL130/UL131 pentameric complex antigen and a Th1 -inducing adjuvant. If further relates to the immunogenic composition for use as an HCMV vaccine.

The invention relates to a live-attenuated yellow fever virus strain adapted to grow on Vero cells from a parent yellow fever virus 17D substrain that is not adapted to grow on Vero cells, wherein said live-attenuated yellow fever virus strain is less neurovirulent than said parent yellow fever virus 17D substrain. ...

The present invention relates to a liposome comprising a saponin, a sterol, a phospholipid and a Toll-like receptor 4 (TLR4) agonist of formula (I), to methods of preparing liposomes, to compositions comprising them and to uses thereof, and to immunogenic compositions comprising such liposomes as adjuvant. ...

The present invention is directed to a set of primers for amplifying by Polymerase Chain Reaction (PCR) a sequence of any mycobacterial rrs gene present in a sample, wherein said set comprises at least three pairs of primers and allows the amplification of a sequence from the rrs gene of any mycobacterial species. T...

The disclosure relates to novel lipidic compounds, method of manufacturing lipid nanoparticles (LNPs) containing thereof, lipid nanoparticles (LNPs) containing thereof, and the use of the LNPs for the delivery of nucleic acid. The lipidic compounds as disclosed herein is a cleavable lipidic compound comprising at le...

Disclosed herein are cell-free protein synthesis systems, reaction mixtures for the same, and methods for preparing a protein of interest.

This invention relates to compositions (e.g., vaccine compositions) which can be used to immunise against Chlamydia infections. The compositions comprise Chlamydia sp. antigens and antigen combinations which can be used to immunise against Chlamydia sp., used in the form of nucleic acids (e.g., mRNAs) encoding antig...